PGDx launched in 2010 to bring innovative genetic analyses to cancer researchers, physicians and patients. PGDx uses cutting-edge next-generation sequencing and analysis techniques to identify mutations in patients’ tumors and facilitate the development of personalized treatment plans as well as novel basic science discoveries. In addition, PGDx has developed exciting liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that will enable non-invasive tumor detection and monitoring. PGDx is composed of talented individuals with a variety of scientific backgrounds that are dedicated to advancing medicine through genomic technologies.